We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.85 | 0.80 | 0.90 | 0.85 | 0.85 | 0.85 | 119,308 | 07:36:40 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 0 | -1.03M | -0.0057 | -1.49 | 1.54M |
TIDMN4P
RNS Number : 9726J
N4 Pharma PLC
04 July 2017
04 July 2017
N4 Pharma Plc
("N4 Pharma" or the "Company")
Filing of Patent
N4 Pharma Plc (AIM: N4P), a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, is pleased to announce the filing of its Patent Cooperation Treaty ("PCT") patent application for the reformulation of Valsartan.
Valsartan is part of a family of drugs known as Angiotensin II antagonists which are commonly used for the treatment of hypertension. N4 Pharma is seeking to reformulate the drug to reduce the impact of an early morning drop in blood pressure. Angiotensin II had global annual sales of approximately $11.2 billion in 2016(*) .
Nigel Theobald, CEO of N4 Pharma, commented: "Our reformulation work on other drugs continues to progress well and we have now generated the required laboratory data to enable us to file our PCT application for Valsartan. We will continue to work on the reformulation to develop the precise drug profile we would need to take it into 'proof of concept' clinical work.
"Sildenafil remains our lead program and we will provide an update at the appropriate time on our plans and timings for the proof of concept clinical work which we plan to do. As this progresses we will continue to investigate reformulations for the other product opportunities in our pipeline."
*Source: Evaluate Pharma
Enquiries:
N4 Pharma Via Alma PR CEO, Nigel Theobald Stockdale Securities Tel: +44(0)207 601 Tom Griffiths 6100 Beaufort Securities Tel: +44(0)207 382 Elliot Hance 8300 Alma PR Tel: +44(0)778 090 Josh Royston 1979 Robyn Fisher Tel: +44(0)754 070 6191
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance. Its shares were admitted to trading on AIM on 3 May 2017.
N4 Pharma's reformulation work falls under two divisions:
-- generic, already commercialised, drugs; and
-- delivery of novel and existing vaccines.
N4 Pharma has identified a number of established drugs that could be improved upon through its reformulation techniques. N4 Pharma's most advanced reformulation is for sildenafil, widely marketed as Viagra, where N4 Pharma is seeking to improve the speed at which the drug takes effect whilst also extending its duration of action.
N4 Pharma's reformulation approach should take approximately three years to obtain regulatory approval as opposed to the traditional process for new drugs of on average ten years. The cost and risk profile of this model is also significantly less than the traditional process. N4 Pharma's business model is to take reformulated drugs from its portfolio through to the stage where it will license its newly reformulated drugs to pharmaceutical companies to commercialise them. N4 Pharma's revenues should be derived from up front milestone and royalty payments associated with the licence.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESEALXDESEXEFF
(END) Dow Jones Newswires
July 04, 2017 02:00 ET (06:00 GMT)
1 Year N4 Pharma Chart |
1 Month N4 Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions